Abstract
Two preparations are available for platelet transfusion: single-donor apheresis platelet concentrates (APC) and pooled platelet concentrates (PPC) prepared from 4-6 whole blood units. Clear advantages of APC over PPC are a markedly reduced donor exposure of recipients, and easier logistics when attempting a complete supply with ABO-identical and Rh-compatible platelet concentrates. Regulations should aim at complete ABO-identical platelet transfusions because major and minor ABO-incompatible platelet transfusions are probably associated with significantly increased morbidity and mortality. The main advantage of PPC is lower costs. Preparation of PPC is however inevitably accompanied by substantial wastage of plasma and red cells. Only major supraregional blood transfusion centers can guarantee full-coverage supply with ABO-identical and Rh-compatible PPC. Whether APC are more effective than PPC and associated with fewer septic platelet transfusion reactions as shown in some but not all studies, has to be examined in future prospective controlled trials. Copyright © 2008 S. Karger AG.
Author supplied keywords
Cite
CITATION STYLE
Hellstern, P. (2008, April). Efficacy and adverse events of platelet transfusion - Product-specific differences. Transfusion Medicine and Hemotherapy. https://doi.org/10.1159/000119117
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.